FDA Grants Fast Track Designation to Oncolytics' Pelareorep Combo in Anal Cancer

The U.S. Food and Drug Administration has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for the treatment of patients with inoperable, locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC) who have progressed on or were intolerant to one or more prior lines of systemic therapy, Oncolytics Biotech Inc. announced on July 20, 2026.

Fast Track designation is intended to facilitate the development and expedite the review of therapies that treat serious diseases and address significant unmet medical needs. The designation provides opportunities for more frequent interactions with the FDA throughout development, rolling review of a future Biologics License Application, and eligibility for Priority Review, if applicable.

The designation follows positive feedback received during the company's April 2026 meeting with the FDA regarding a potential registrational development strategy for the program. Based on the FDA's feedback, Oncolytics believes it has a clear regulatory framework in place to advance pelareorep toward a pivotal study in this indication.

The designation is supported by encouraging efficacy demonstrated in the company's GOBLET study evaluating pelareorep in combination with a checkpoint inhibitor in patients with advanced SCAC whose disease had progressed following prior therapy. Previously reported clinical results demonstrated an objective response rate of approximately 30%, more than double historical response rates reported in this setting, a median duration of response of approximately 15.5 months versus 9.5 months, and 12-month overall survival rate of 82% compared to 45.7%.

With checkpoint inhibitor plus chemotherapy now established as the first-line standard of care in SCAC, there remains no FDA-approved therapies for patients whose disease progresses following such treatment, representing a significant unmet medical need and an estimated U.S. commercial opportunity approaching $1 billion annually. Although checkpoint therapy is also approved as a single agent following progression or intolerance to platinum-based chemotherapy alone, no checkpoint inhibitor has been approved for patients who progress after receiving the current first-line standard of care regimen.

The Fast Track designation in SCAC is the third gastrointestinal cancer designation granted to pelareorep by the FDA, following designations in KRAS-mutated metastatic colorectal cancer in February 2026 and pancreatic cancer in late 2022.

Pelareorep is an intravenously delivered, systemically active, investigational immunotherapy with a dual mechanism of action that selectively replicates in tumor cells while activating both innate and adaptive anti-tumor immune responses, including the upregulation of key inflammatory cytokines resulting in the formation of tertiary lymphoid structures and the expansion of tumor-infiltrating lymphocytes.